Page last updated: 2024-08-24

enadoline and Parkinson Disease, Secondary

enadoline has been researched along with Parkinson Disease, Secondary in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brotchie, JM; Crossman, AR; Maneuf, YP; Mitchell, IJ; Woodruff, GN1
Brotchie, JM; Crossman, AR; Hill, MP; Hughes, NR; McKnight, AT; Woodruff, GN1
Brotchie, JM; Hill, MP1

Other Studies

3 other study(ies) available for enadoline and Parkinson Disease, Secondary

ArticleYear
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.
    Brain research, 1995, Jun-12, Volume: 683, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Arrhythmia Agents; Basal Ganglia; Benzofurans; Callithrix; Female; Glutamic Acid; In Vitro Techniques; Male; Motor Activity; Naltrexone; Parkinson Disease, Secondary; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reserpine; Synaptic Transmission

1995
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:2

    Topics: alpha-Methyltyrosine; Animals; Antiparkinson Agents; Benzeneacetamides; Benzofurans; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reserpine

1998
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
    British journal of pharmacology, 1999, Volume: 128, Issue:7

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzofurans; Biogenic Monoamines; Clonidine; Disease Models, Animal; Drug Combinations; Drug Synergism; Locomotion; Male; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Prazosin; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reserpine; Yohimbine

1999